Skip to content

Ketamine research published in 2025

Page 28 of 39: studies 541 to 560 of 780, newest first. Back to the ketamine overview

Studies

Using cluster analysis to investigate consumption patterns in cases positive to ketamine: a national 7-year study.

Naunyn-Schmiedeberg's Archives of Pharmacology March 14, 2025 Shyh-Yuh Wei, Chien-Chou Su, Hsuan-Yun Hu et al. 1 citation

The use of ketamine has increased; however, actual consumption patterns and ketamine-related deaths remain poorly understood. This study aimed to (1) cluster the consumption patterns of individuals who consume ketamine and (2) investigate their associations with manner and cause of death. A retrospective study was conducted on all cases positive to ketamine at death, retrieved from the...

DOI: 10.1007/s00210-025-04019-9 (opens in new tab) Full text (opens in new tab) Substance abuse Drug interactions Addiction research Toxicology +6

Person-centred care during treatment with nasal esketamine - a qualitative study.

BMC Nursing March 14, 2025 Lina Klysing, Ingrid Larsson, Katrin Häggström Westberg 2 citations

Patients suffering from treatment-resistant depression may be treated with nasal esketamine. The treatment requires administration in a healthcare facility and monitoring by a nurse. Existing research has mainly focused on the clinical effect of nasal esketamine, while less is known about patients' experiences of treatment. A person-centred framework provides valuable insights into care and...

DOI: 10.1186/s12912-025-02943-y (opens in new tab) Full text (opens in new tab) Intranasal ketamine Nursing Nasal esketamine Person-centred care +4

Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study.

Molecular therapy. Methods & clinical development March 13, 2025 Huiping Li, Shu Liu, Caimei Lin et al. 5 citations

Rett syndrome (RTT) is a severe neurodevelopmental disorder. N-Methyl-d-aspartate receptor (NMDAR) antagonism has shown therapeutic potential in preclinical RTT models. We performed a pilot study to explore whether intravenous esketamine, an NMDAR antagonist, alleviates the symptoms of pediatric RTT. This was a prospective, single-arm, single-site, open-label, early phase 1 pilot study. Three...

DOI: 10.1016/j.omtm.2025.101413 (opens in new tab) Full text (opens in new tab) Esketamine N-methyl-d-aspartate receptor antagonist Rett syndrome Efficiency +6

Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey.

JMIR Formative Research March 11, 2025 Mollie R Cummins, Julia Ivanova, Hiral Soni et al. 3 citations

In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental health care provider shortages. However, as lawmakers consider long-term telemedicine policy decisions, some question the safety and appropriateness of prescribing via telemedicine, and whether there should be requirements for in-person evaluation,...

DOI: 10.2196/63251 (opens in new tab) Full text (opens in new tab) Ketamine Telehealth telemedicine Digital health Mental health telemental +17

Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.

Translational Psychiatry March 8, 2025 Daiki Nakatsuka, Taro Suwa, Yuichi Deguchi et al. 1 citation

Ketamine, a rapid-acting antidepressant, has undesirable psychotomimetic effects, including a dissociative effect. There is currently no effective strategy to suppress these side effects while preserving its antidepressant effect. Here, we investigated the effects of a D2/D3 receptor antagonist and partial agonists on the psychotomimetic and antidepressant effects of ketamine in mice and...

DOI: 10.1038/s41398-025-03284-9 (opens in new tab) Full text (opens in new tab) Ketamine therapy Antidepressant medication Mental health treatment Psychiatric research +1

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Journal of the American Academy of Child & Adolescent Psychiatry March 7, 2025 Colette Kosik-Gonzalez, Dong-Jing Fu, Li Nancy Chen et al. 14 citations

To evaluate the efficacy, safety, and tolerability of esketamine nasal spray vs psychoactive placebo (oral midazolam) in rapidly reducing depressive symptoms in adolescents with major depressive disorder at imminent risk for suicide. This double-blind, double-dummy, phase 2b study randomized (1:1:1:2) 147 adolescents (12 to <18 years old) to esketamine (28, 56, or 84 mg) or midazolam twice...

Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.

Journal of Addictive Diseases March 6, 2025 Christopher Lomas 2 citations

This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic interventions. Patterns of misuse demonstrate the complex interplay of neurobiological, socio-economic, demographic and psychological factors with adolescents, women and polysubstance users identified as high-risk groups. Neurobiological findings...

Effect of esketamine on reducing postpartum pain and depression.

World Journal of Clinical Cases March 6, 2025 Brandon P Lucke-Wold, Armin Karamian 9 citations

In this editorial, we comment on a recent article by Chen et al, that addressed the effect of intraoperative injection of esketamine on postoperative analgesia and postoperative rehabilitation after cesarean section. Poor management of post-cesarean pain is associated with decreased maternal care for the baby, longer hospitalization, and higher risk of developing postpartum depression....

DOI: 10.12998/wjcc.v13.i7.100422 (opens in new tab) Full text (opens in new tab) Cesarean-section c-section Esketamine-therapy ketamine treatment Postpartum-depression postnatal depression Baby blues +8

Gastrodin Mitigates Ketamine-Induced Inhibition of F-Actin Remodeling and Cell Migration by Regulating the Rho Signaling Pathway.

Biomedicines March 6, 2025 Ping-Cheng Shih, I-Shiang Tzeng, Yi-Chyan Chen et al. 1 citation

Background/Objects: Rho signaling plays a role in calcium-regulated cytoskeletal reorganization and cell movement, processes linked to neuronal function and cancer metastasis. Gastrodia elata, a traditional herbal medicine, can regulate glutamate-induced calcium influx in PC12 cells and influence cell function by modulating neuronal cytoskeleton remodeling via the monoaminergic system and Rho...

S-ketamine alleviates morphine-induced hyperalgesia via decreasing the gut Enterobacteriaceae levels: Comparison with R-ketamine.

Neuroscience March 5, 2025 Hanyu Liu, Siqi Yang, Qi Zhang et al.

Opioid-induced hyperalgesia (OIH) is a serious complication during the pain treatment. Ketamine has been commonly reported to treat OIH, but the mechanisms remain unclear. Gut microbiota is recently recognized as one of the important mechanisms underlying the occurrence and treatment of OIH. However, whether ketamine enantiomers could alleviate OIH through gut microbiota that still needs to be...

DOI: 10.1016/j.neuroscience.2025.01.022 (opens in new tab) Full text (opens in new tab) R-ketamine Gut microbiota Opioid-induced hyperalgesia Pain management +7

Discovery of a Novel Orally Active Ketamine Derivative with Dual Analgesic and Antidepressant Activities, Lacking Psychomimetic Effects.

ACS Chemical Neuroscience March 5, 2025 Syed Muzzammil Masaud, Humaira Nadeem, Babar Murtaza et al. 3 citations

This study investigated the synthesis, characterization, and in silico analysis of novel N-acetamide ketamine derivatives aimed at evaluating their analgesic, anesthetic, and antidepressant properties. The synthesis commenced with the preparation of chloroacetylamide derivatives, which were subsequently reacted with ketamine hydrochloride, yielding 16 derivatives k1 to k16. These compounds were...

DOI: 10.1021/acschemneuro.4c00887 (opens in new tab) Full text (opens in new tab) Anesthetic Psychomimetic Pain-relief analgesic Pain management +6

Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review.

Current reviews in clinical and experimental pharmacology March 3, 2025 Sin Hui Ng, Yu Zhao Lee, Ming Ye Hong et al. 2 citations

Ketamine, a substance used for anesthesia and known for inducing dissociation, can lead to addiction and the development of severe withdrawal symptoms. Ketamine alters brain networks before affecting somesthetic sensation. Ketamine abuse was especially prevalent in East and Southeast Asia, and its popularity has continued to expand globally in recent decades. Ketamine is gaining popularity in...

Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)

medRxiv Preprint Server March 2, 2025 Bonnie L. Quigley, Emerald Orr, Sophie Kafka et al. preprint

Ketamine has been investigated as a treatment alternative for PTSD for the last 20 years, yet there have been virtually no reports of biological changes or biomarker characterisation related to treatment. To address this significant gap, this study analysed blood samples from 25 participants with PTSD who took part in an open-label 6-week trial of low dose oral ketamine treatment. Serum and...

Analysis of trial confirms efficacy of esketamine nasal spray in TRD

The Brown University Psychopharmacology Update March 1, 2025

Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in The British Journal of...

The Impact of Ketamine-Based Versus Non-Ketamine-Based ECT Anesthesia Regimens on the Severity of Patients’ Depression and Occurrence of Adverse Events: A Systematic Review with Meta-Analysis

Annals of Pharmacotherapy March 1, 2025 Dakota Sicignano, Rohan Kantesaria, Matthew Mastropietro et al.

Objective: To compare efficacy and safety outcomes for ketamine anesthesia + electroconvulsive therapy (ECT) versus nonketamine anesthesia + ECT in treatment-resistant depression (TRD) patients. Data Sources: PubMed and Embase were searched from the earliest date through November 27, 2023. Study Selection and Data Extraction: Relevant randomized controlled trials (RCTs) of ketamine + ECT versus...

Xylazine as an emerging new psychoactive substance; focuses on both 5‐HT7 and κ‐opioid receptors' molecular interactions and isosteric replacement

Archiv der Pharmazie March 1, 2025 Giuseppe Floresta, Alberto Granzotto, Vincenzo Patamia et al. 12 citations

Abstract Xylazine, traditionally used as a veterinary sedative, has recently emerged as a new psychoactive substance, being typically ingested in combination with fentanyl derivatives and hence raising significant public health concerns. Despite its increasing prevalence, little is known about its molecular interactions with human neuroreceptors, specifically the serotonin 7 (5‐HT 7 R) and...

Clinical analysis of dexmedetomidine-esketamine combined with intranasal administration before laparoscopic high ligation of hernia sac in infants and young children.

African health sciences March 1, 2025 Cuicui Shi, Chuanyue Zong, Jia Yang et al.

Studying To investigate the clinical values of dexmedetomidine and esketamine combined with intranasal infusion before laparoscopic high ligation of hernia sacs in infants and young children. In our hospital, 90Ninety children aged 8-14 years underwent surgical high ligation of the hernia sac between March 2021 and March 2022 were included. During March 2021 to March 2022, 90 children aged 8-14...

Ketamine Use for Palliative Care in the Austere Environment: Is Ketamine the Path Forward for Palliative Care.

The American journal of hospice & palliative care March 1, 2025 John R Reed, Stephanie K Parks, Antony Kaniaru et al. 1 citation

The goal of palliative care is to focus on the holistic needs of the patient and their family versus the pathology of the patient's diagnosis to reduce the stress of illness. U.S. servicemembers deployed to austere environments worldwide have significantly less access to palliative care than in military treatment facilities in the U.S. Preparation for future conflicts introduces the concept of...

DOI: 10.1177/10499091241246520 (opens in new tab) Full text (opens in new tab) Combat care Pain management Palliative care Suffering +3

Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy.

Wiener klinische Wochenschrift March 1, 2025 Pia Baldinger-Melich, Marie Spies, Ina Bozic et al. 5 citations

Modern electroconvulsive therapy (ECT) and the approval of nasal esketamine for clinical use have significantly improved the approach to treatment-resistant depression (TRD), which is defined as non-response to at least two different courses of antidepressants with verified adherence to treatment, adequate dosage, and duration of treatment. The goal of this literature review is to present the...

DOI: 10.1007/s00508-024-02358-w (opens in new tab) Full text (opens in new tab) Spravato Antidepressant treatment Electroconvulsive therapy ect Treatment-resistant depression trd +6

A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial).

The American journal of hospice & palliative care March 1, 2025 Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh et al. 4 citations

Ketamine has been used to control refractory cancer pain as an adjuvant to opioids. We conducted a prospective phase II study to investigate the efficacy and safety of 5-day continuous intravenous infusion (CIVI) of Ketamine in terminally ill cancer patients with refractory cancer pain. Hospitalized terminally ill cancer patients with refractory cancer pain were enrolled. Refractory cancer pain...

DOI: 10.1177/10499091241252977 (opens in new tab) Full text (opens in new tab) Opioid Palliative care Refractory cancer pain Cancer pain treatment +4